Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Escitalopram. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 14/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.89 |
| ▸ | HTR2C | P28335 | 2/20 | 0.89 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.89 |
| ▸ | HRH1 | P35367 | 2/20 | 0.89 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.89 |
| ▸ | DRD3 | P35462 | 2/20 | 0.89 |
| ▸ | HTR2B | P41595 | 2/20 | 0.89 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.89 |
| ▸ | NPC1 | O15118 | 1/20 | 0.89 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.89 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.89 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.89 |
| ▸ | HTR1A | P08908 | 1/20 | 0.89 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.89 |
| ▸ | DRD1 | P21728 | 1/20 | 0.89 |
| ▸ | ACHE | P22303 | 1/20 | 0.89 |
| ▸ | HRH2 | P25021 | 1/20 | 0.89 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Citalopram SCHEMBL2010566 | 1.00 | SLC6A4 (1.00) | SLC6A4MAPK1LMNASLC6A2HTR2C | |
| Escitalopram SCHEMBL30223023 | 1.00 | SLC6A4 (1.00) | SLC6A4MAPK1LMNASLC6A2HTR2C | |
| Citalopram SCHEMBL29604018 | 1.00 | SLC6A4 (1.00) | SLC6A4MAPK1LMNASLC6A2HTR2C | |
| Escitalopram SCHEMBL27936829 | 1.00 | SLC6A4 (1.00) | SLC6A4MAPK1LMNASLC6A2HTR2C | |
| Citalopram SCHEMBL28369040 | 1.00 | SLC6A4 (1.00) | SLC6A4MAPK1LMNASLC6A2HTR2C | |
| Escitalopram SCHEMBL28980945 | 0.97 | SLC6A4 (0.94) | SLC6A4MAPK1LMNASLC6A2HTR2C | |
| Escitalopram SCHEMBL28631467 | 0.97 | SLC6A4 (0.94) | SLC6A4MAPK1LMNASLC6A2HTR2C | |
| Citalopram SCHEMBL3287650 | 0.94 | SLC6A4 (0.90) | SLC6A4MAPK1LMNASLC6A2HTR2C | |
| (R)-Citalopram SCHEMBL13235283 | 0.94 | SLC6A4 (1.00) | SLC6A4MAPK1LMNASLC6A2HTR2C | |
| Citalopram SCHEMBL946 | 0.94 | SLC6A4 (1.00) | SLC6A4MAPK1LMNASLC6A2HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2701 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260131089-A1 | DRUG DELIVERY DEVICES AND METHODS FOR ADMINISTERING SUBSTANCES TO A BODY CAVITY BY HETEROGENOUS AEROSOLIZATION FOR TREATMENT OF BINGE-EATING DISORDERS AND/OR OBESITY | APTARGROUP, INC. (US) | 2026-05-14 | — | — | US | claimed |
| EP-4740962-A1 | PHARMACEUTICAL COMPOSITION, FORMULATION CONTAINING PHARMACEUTICAL COMPOSITION, KIT CONTAINING PHARMACEUTICAL COMPOSITION, PREPARATION METHOD FOR PHARMACEUTICAL COMPOSITION, AND USE OF PHARMACEUTICAL COMPOSITION | Shanghai WD Pharmaceutical Co., Ltd (CN) | 2026-05-13 | — | — | EP | claimed |
| US-12624036-B2 | Method of treating post-traumatic stress disorder | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-05-12 | — | — | US | claimed |
| US-12624037-B2 | Method of treating agitation, aggressive behavior, and impulse control disorder | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-05-12 | — | — | US | claimed |
| US-20260034065-A1 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION | DOUGLAS PHARMACEUTICALS LTD (NZ) | 2026-02-05 | — | — | US | claimed |
| EP-4661849-A1 | AN IMMEDIATE-RELEASE ORAL PHARMACEUTICAL FORM OF ESCITALOPRAM OR RACEMATE THEREOF WITH INCREASED API CONTENT | Kinast, Lasse (DE) | 2025-12-17 | — | — | EP | claimed |
| US-20250375418-A1 | 1-(NAPHTHALEN-2-YL)-3-AZABICYCLO[3.1.0]HEXANE FOR TREATING MAJOR DEPRESSIVE DISORDER | OTSUKA PHARMA CO LTD (JP) | 2025-12-11 | — | — | US | claimed |
| US-12491325-B2 | Drug delivery devices and methods for administering substances to a body cavity by heterogenous aerosolization for treatment of binge-eating disorders and/or obesity | APTARGROUP, INC. (US) | 2025-12-09 | — | — | US | claimed |
| US-12472146-B2 | Extended release pharmaceutical formulation | DOUGLAS PHARMACEUTICALS, LTD. (NZ) | 2025-11-18 | — | — | US | claimed |
| EP-4580605-A1 | 1-(NAPHTHALEN-2-YL)-3-AZABICYCLO[3.1.0]HEXANE FOR TREATING MAJOR DEPRESSIVE DISORDER | Otsuka Pharmaceutical Co., Ltd. (JP) | 2025-07-09 | — | — | EP | claimed |
| US-20050014743-A1 | Combination of an NMDA receptor antagonist and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders | FOREST LABORATORIES, INC. (US) | 2005-01-20 | — | — | US | claimed |
| EP-1414435-B1 | CRYSTALLINE COMPOSITION CONTAINING ESCITALOPRAM | LUNDBECK & CO AS H (DK) | 2005-01-12 | — | — | EP | claimed |
| WO-2005000216-A2 | COMBINATION OF AN NMDA RECEPTOR ANTAGONIST AND A SELECTIVE SEROTONIN REUPTAKE INHIBITOR FOR THE TREATMENT OF DEPRESSION AND OTHER MOOD DISORDERS | FOREST LABORATORIES, INC. (US) | 2005-01-06 | — | — | WO | claimed |
| US-20040171664-A1 | Compositions of cyclooxygenase-2 selective inhibitors and selective serotonin reuptake inhibitors for the treatment or prevention of a vaso-occlusive event | PHARMACIA CORPORATION | 2004-09-02 | — | — | US | claimed |
| WO-2004058354-A1 | COMPOSITIONS OF CYCLOOXYGENASE-2 SELECTIVE INHIBITORS AND SELECTIVE SEROTONIN REUPTAKE INHIBITORS FOR THE TREATMENT OR PREVENTION OF A VASO-OCCLUSIVE EVENT | PHARMACIA CORPORATION (US) | 2004-07-15 | — | — | WO | claimed |
| WO-2004058229-A1 | MODIFIED RELEASE FORMULATIONS OF SELECTIVE SEROTONIN RE-UPTAKE INHIBITORS | BIOVAIL LABORATORIES INC. (BB) | 2004-07-15 | — | — | WO | claimed |
| EP-1414435-A1 | CRYSTALLINE COMPOSITION CONTAINING ESCITALOPRAM | H. Lundbeck A/S (DK) | 2004-05-06 | — | — | EP | claimed |
| US-20040029958-A1 | Treatment of neurotic disorders | H. LUNDBECK A/S | 2004-02-12 | — | — | US | claimed |
| US-20030212128-A1 | Crystalline composition containing escitalopram | H. LUNDBECK A/S (DK) | 2003-11-13 | — | — | US | claimed |
| WO-2003011278-A1 | CRYSTALLINE COMPOSITION CONTAINING ESCITALOPRAM | H. LUNDBECK A/S (DK) | 2003-02-13 | — | — | WO | claimed |